A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) is a biopharmaceutical company focused on developing therapies for patients with cardiovascular diseases and unmet medical needs. The company is advancing programs intended to address critical treatment gaps while improving...
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is developing differentiated products designed to bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations. This fireside chat was recorded during the Lytham...
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing transformative therapeutics to address limitations of current anticoagulation therapy. This company webcast was recorded during the Lytham Partners Fall 2025 Investor Conference.
During this fireside chat we welcome Cadrenal Therapeutics (Nasdaq: CVKD). Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart...
Cadrenal Therapeutics (Nasdaq: CVKD) is a late-stage biopharmaceutical company boldly challenging the status quo by innovating a new anticoagulant to elevate care for underserved patients. The company is developing the vitamin K antagonist (VKA) tecarfarin, designed...
During this company webcast, we welcome Cadrenal Therapeutics, ticker symbol of CVKD on the Nasdaq. And joining us today from the company is Quang Pham. Quang is the Founder, Chairman and CEO of Cadrenal. Cadrenal Therapeutics is developing tecarfarin for unmet needs...
During this fireside chat we welcome Cadrenal Therapeutics, ticker symbol of CVKD on the Nasdaq. Joining us from the company is the company’s Chief Medical Officer, Dr. Douglas Losordo. Also joining us is Joe Pantginis. Joe is the Managing Director of Research at H.C....
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner), to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain rare medical conditions who require chronic anticoagulation....
In this panel companies discuss developments in the broader market, as well as their unique late-stage drugs looking to address cardiac-based indications. Panelists include Quang Pham, Chairman & CEO at Cadrenal Therapeutics and Craig Fraser, CEO at Windtree...
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) with orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage...
This panel presentation features executives from three different companies that are looking to advance innovations in healthcare, each of them with ongoing or planned Phase 3 trials here. We've titled the panel, Phase 3 Drugs to Watch. Hosted by Lytham Partners...